logo

Moleculin Biotech Inc (MBRX)



Trade MBRX now with
  Date
  Headline
9/27/2022 8:38:08 AM Moleculin : WP1122 Portfolio Compound, WP1096, Selected For NIAID-Funded Animal Studies As Novel Potential Antiviral
9/6/2022 8:49:22 AM Moleculin Gets FDA Orphan Drug Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme
8/19/2022 8:42:27 AM Moleculin Completes Third Single Ascending Dose Cohort In Phase 1a Trial Of WP1122 In The UK
8/15/2022 8:40:29 AM Moleculin Biotech Q2 Loss/shr Widens To $0.24 From $0.15 Prior Year
7/28/2022 8:36:51 AM Moleculin Concludes Phase 1b And Opens Recruitment In Phase 2 Trial Of Annamycin For Soft Tissue Sarcoma Lung Metastases
7/8/2022 8:39:01 AM Moleculin Announces Completion Of Second Single Ascending Dose Cohort In Phase 1a Trial Of WP1122 In UK
6/16/2022 8:40:47 AM Moleculin Completes First Single Ascending Dose Cohort In Phase 1a Clinical Trial Of WP1122 In UK
5/26/2022 8:38:02 AM Moleculin Commences Dosing In Healthy Volunteers In Phase 1a Trial Of WP1122 For Treatment Of COVID-19
5/10/2022 8:36:48 AM Moleculin Receives UK Approval For Protocol Amendment To Phase 1a Trial Of WP1122 For Treatment Of COVID-19